Shree Ganesh Biotech (India) Ltd (SHREEGANES)

Loading page…

Shree Ganesh Biotech (India) Ltd (SHREEGANES) · mywealthgrid

About

Shree Ganesh Biotech (India) Ltd operates in Biotechnology within the Healthcare sector.

Face value: ₹1

Market cap

₹19 Cr

P/E

48.4×

P/B

0.3×

Dividend yield

ROE

0.6%

ROCE

0.8%

Debt / equity

OPM

-19.3%

EPS (TTM)

₹0.0

Book value

₹1.6

52-week high

—

52-week low

—

1,142 historical price candles were omitted because the exchange source has not been verified.

₹0.5-2.1%1Y

Quick read

rule-based

Pros

+Almost debt-free (debt/equity 0)

Cons

−Low return on equity of 0.7% (3-yr avg)
−Revenue shrank over the last 5 years (-22% a year)

Research score

Structured signal from quality, growth, valuation and momentum.

28/100

Business quality: 25
Growth: 0
Valuation: 59

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Screen this industry Compare top 5 side-by-side

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	9	8	6	2	17	73	62	20	23	5
COGS	-4	-3	-3	-2	16	69	60	20	23	5
Gross profit	—	—	—	—	1	4	3	0	0	-0
	9	8	7	4	0	0	1	0	1	1
	4	4	2	0	1	3	2	-0	-1	-1
OPM %	44.3%	44.5%	30.5%	9.3%	4.1%	4.7%	3.4%	-1%	-4.6%	-19.3%
Depreciation	—	—	—	—	0	0	0	0	0	0
Interest	0	—	—	—	0	0	0	0	0	0
	—	—	—	—	-0	0	1	1	1	1
Profit before tax	4	4	2	0	0	4	3	1	0	1
Tax	—	—	—	—	0	1	1	0	0	0
Tax %	—	—	—	—	25.6%	27.7%	25.1%	27.1%	28.2%	27.5%
	4	4	2	0	0	3	2	1	0	0
PAT margin %	43.7%	44.5%	30.5%	9.7%	1.9%	3.5%	3.3%	3.1%	1.2%	7.7%
EPS (₹)	—	19.1	1.8	0.1	0.2	0.1	0.1	0	0	0
EPS adjusted (₹)	—	—	—	—	0	0.1	0.1	0	0	0
Annual report	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2019	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	20	20	40	40	40	40
Reserves	38	40	22	23	23	24
Minority interest	—	—	0	—	0	—
	0	0	0	0	0	0
	17	33	17	11	0	0
Total equity & liabilities	75	94	80	74	63	64
	0	0	0	0	0	0
CWIP	0	0	0	0	0	0
Investments	3	3	0	0	9	9
	72	90	80	74	54	55
Total assets	75	94	80	74	63	64

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	5.1%	5.2%	4.5%	1.2%	1.4%	-1.8%
EBITDA margin %	30.5%	9.3%	4.1%	4.7%	3.4%	-1%	-4.6%	-19.3%
EBIT margin %	30.5%	9.3%	4.1%	4.7%	3.4%	-1%	-4.6%	-19.3%
PAT margin %	30.5%	9.7%	1.9%	3.5%	3.3%	3.1%	1.2%	7.7%
Working capital
Receivable days	—	—	601	221	113	59	0	0
Inventory days	—	—	0	0	0	0	47	846
Payable days	—	—	369	171	101	189	0	0
NWC days	—	—	232	49	12	-129	47	846
Leverage
Current ratio	—	—	4.3	2.72	4.63	0.35	54.52	70
Debt to EBITDA	—	—	0.27	0	0	—	—	—
Debt to equity	—	—	0	0	0	0	0	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0.23	0.78	0.79	0.28	0.36	0.08
Return ratios
Return on assets %	—	—	0.4%	2.7%	2.6%	0.8%	0.4%	0.6%
Return on capital employed %	—	—	1.2%	5.9%	4.4%	1.4%	0.6%	0.8%
Return on equity %	—	—	0.6%	4.2%	3.3%	1%	0.4%	0.6%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoter	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	2.17%	2.17%	1.42%	1.42%	1.42%	1.42%	1.42%	1.42%	1.42%	1.42%	1.42%	1.42%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	97.83%	97.83%	98.58%	98.58%	98.58%	98.58%	98.58%	98.58%	98.58%	98.58%	98.58%	98.58%
No. of shareholders	—	—	—	—	—	—	—	—	1,89,375	1,86,148	1,83,658	1,81,722

Promoter holding up 0 percentage points since Sep 2023.

15 deals · 20 Dec 2021 – 27 Mar 2024

Date	Client	Type	Venue	Side	Quantity	Price	Value
27 Mar 2024	NEW ERA FUND LIMITED	Bulk	BSE	Sell	30,00,000	₹1.10	₹0.33 Cr
8 Jan 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Sell	29,58,016	₹1.47	₹0.43 Cr
8 Jan 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Buy	5,00,000	₹1.47	₹0.07 Cr
5 Jan 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Sell	86,37,984	₹1.56	₹1.35 Cr
4 Jan 2024	TOPGAIN FINANCE PRIVATE LIMITED	Bulk	BSE	Buy	1,15,96,000	₹1.49	₹1.73 Cr
4 Jan 2024	SHRI CHAND	Bulk	BSE	Sell	30,12,000	₹1.48	₹0.45 Cr
4 Jan 2024	SETU SECURITIES PVT. LTD.	Bulk	BSE	Buy	25,68,661	₹1.48	₹0.38 Cr
20 Dec 2023	ASHOK KUMAR	Bulk	BSE	Buy	44,10,000	₹1.33	₹0.59 Cr
14 Dec 2023	NATTAYA CHOWDHURY	Bulk	BSE	Sell	60,00,000	₹1.11	₹0.67 Cr
14 Dec 2023	SHRI CHAND	Bulk	BSE	Buy	26,60,000	₹1.14	₹0.30 Cr

1–10 of 15

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mr. AMAN PRAVINKUMAR PATELExecutive Director-Chairperson
Mr. SOMBIR SINGHNon-Executive - Independent Director
Mr. KISHAN NITYANAND NAIDUExecutive Director
Mr. NIMESHKUMAR MOHANBHAI PARMARNon-Executive - Independent Director
Ms. AMRUTABEN RAJANBHAI SOLANKINon-Executive - Independent Director
Mr. HARSHADKUMAR RATHODNon-Executive - Independent Director
Ms. Namita AcharyaCompany Secretary and Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

No fund holdings on record

No scheme among the 32 fund houses on record reported a position in Shree Ganesh Biotech (India) Ltd. Portfolios are published monthly by each AMC; coverage is still partial.

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

1

Board meeting to consider results4 Aug 2026

1

Face value ₹10 → ₹110 Feb 2022 · ex-date

1

Bonus 1:127 Apr 2022 · ex-date

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

40 announcementsExport CSV

7 Jul 2026, 6:00 pmCompany Update

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 PDF

Loading announcements…

Ratio	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	5.1%	5.2%	4.5%	1.2%	1.4%	-1.8%
EBITDA margin %	30.5%	9.3%	4.1%	4.7%	3.4%	-1%	-4.6%	-19.3%
EBIT margin %	30.5%	9.3%	4.1%	4.7%	3.4%	-1%	-4.6%	-19.3%
PAT margin %	30.5%	9.7%	1.9%	3.5%	3.3%	3.1%	1.2%	7.7%
Working capital
Receivable days	—	—	601	221	113	59	0	0
Inventory days	—	—	0	0	0	0	47	846
Payable days	—	—	369	171	101	189	0	0
NWC days	—	—	232	49	12	-129	47	846
Leverage
Current ratio	—	—	4.3	2.72	4.63	0.35	54.52	70
Debt to EBITDA	—	—	0.27	0	0	—	—	—
Debt to equity	—	—	0	0	0	0	0	0
Interest coverage	—	—	—	—	—	—	—	—
Asset turnover	—	—	0.23	0.78	0.79	0.28	0.36	0.08
Return ratios
Return on assets %	—	—	0.4%	2.7%	2.6%	0.8%	0.4%	0.6%
Return on capital employed %	—	—	1.2%	5.9%	4.4%	1.4%	0.6%	0.8%
Return on equity %	—	—	0.6%	4.2%	3.3%	1%	0.4%	0.6%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Anthem Biosciences LimitedANTHEMANTHEM	₹48,213 Cr	₹48,264 Cr	₹2,002 Cr	₹793 Cr	39.3%	₹576 Cr	27.9%	27.6%	19.5%	124
Advanced Enzyme Technologies LimitedADVENZYMESADVENZYMES	₹3,072 Cr	₹3,092 Cr	₹750 Cr	₹224 Cr	30.7%	₹166 Cr	23.3%	13.7%	11.1%	331
CCME Global LtdCCMECCME	₹54 Cr	₹54 Cr	₹0 Cr	₹0 Cr	—	₹4 Cr	—	-2.9%	-2.9%	—
Vivo Bio Tech LtdVIVOBIOTVIVOBIOT	₹38 Cr	₹92 Cr	₹47 Cr	₹21 Cr	44%	₹7 Cr	15.6%	15.2%	11%	517
Shree Ganesh Biotech (India) LtdSHREEGANESSHREEGANES	₹19 Cr	₹19 Cr	₹23 Cr	₹-1 Cr	-19.3%	₹0 Cr	7.7%	0.8%	0.6%	846
Genomic Valley Biotech LtdGVBLGVBL	₹9 Cr	₹9 Cr	₹0 Cr	₹-0 Cr	14.8%	₹-1 Cr	11.1%	1%	0.8%	3,565

Date	Category	Subject	Filing
7 Jul 2026, 6:00 pm	Company Update Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018	PDF
12 Jun 2026, 5:35 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
23 May 2026, 6:35 pm	Company Update Reg.24(A)-Annual Secretarial Compliance	Compliances-Reg.24(A)-Annual Secretarial Compliance	PDF
14 May 2026, 5:49 pm	Company Update Reg. 32 (1), (3) - Statement of Deviation & Variation	Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015	PDF
14 May 2026, 5:41 pm	Result Financial Results	Regulation 33 Read With Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")	PDF
14 May 2026, 5:37 pm	Board Meeting Outcome of Board Meeting	Board Meeting Outcome for Audited Financial Results Of The Company For The Quarter And Year Ended On 31St March, 2026 And Outcome Of The Board Meeting Held On Thursday 14Th May 2026.	PDF
4 May 2026, 4:46 pm	Board Meeting	Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.	PDF
23 Apr 2026, 6:21 pm	Others Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A	Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A	PDF

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3	0	-3	10	-10	-8
	-3	-0	3	-10	10	8
	0	-0	0	0	0	0
Net cash flow	0	0	0	-0	-0	-0
Free cash flow	3	0	-3	10	-10	-8
CFO / Operating profit %	438.6%	10.5%	-129.4%	—	—	—

Shree Ganesh Biotech (India) Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

1

1

Announcements

Not in the F&O segment

No fund holdings on record

1

1

1

Announcements

Annual reports

Compounded sales growth

Compounded profit growth

Return on equity

Shree Ganesh Biotech (India) Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Stock splits1

Bonus issues1

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

No fund holdings on record

Board meetings1

Stock splits1

Bonus issues1

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

1

1

1

1

1

1